Curi Bio closes $10M oversubscribed Series A led by Dynamk Capital with new investors UTC Investment and DS Asset Management

Curi Bio closed a $10M oversubscribed Series A second closing to scale its human stem cell–based Curi Engine and Mantarray platforms, aiming to accelerate development of 3D engineered muscle tissue models for drug discovery.

More: GeekWire, MobiHealthNews

No comments yet.